臨床に直結する血栓止血学　改訂2版

出版社： 中外医学社
著者：
発行日： 2018-10-20
分野： 臨床医学：内科  >  血液
ISBN： 9784498125797
電子書籍版： 2018-10-20 （2版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

10,780 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

10,780 円(税込)

購入する

商品紹介

前版（2013年）より数多くの進展がみられる血栓止血学の領域について、専門外の読者にもわかりやすく、すぐに役立つ知識を中心に解説した入門書の改訂2版。大幅なボリュームアップ、「ポイント」「ここがコンサルトされやすい！」「症例紹介」「ピットフォール」「お役立ち情報」の記載などにより、「臨床に直結」した内容のさらなる充実を図りました。血栓止血のエキスパートではない一般臨床医、血液専門医、他科専門医、研修医、臨床検査技師、薬剤師、医学生、保健学科学生の方々に特に役立つ一冊です。

目次

  • 1章　総論
    2章　血栓止血関連検査
    3章　出血性疾患
    4章　血小板数低下を伴う血栓性疾患
    5章　血栓性疾患
    6章　抗血栓療法
    7章　血液製剤・止血剤

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

2章 血栓止血関連検査

P.20 掲載の参考文献
1) Rosing J, et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980 ; 255 : 274.
PubMed
2) Davie EW, et al. Waterfall sequence for intrinsic blood clotting. Science. 1964 ; 145 : 1310.
PubMed
3) Litvinov RI. Polymerization of fibrin : Direct observation and quantification of individual B : b knob-hole interactions. Blood. 2007 ; 109 : 130.
 
4) 橋口照人. 凝固・線溶データのみかたと考え方. 臨床血液. 2017 ; 58 : 288.
 
5) 日本検査血液学会標準化委員会凝固検査標準化ワーキンググループ. 凝固検査検体取扱いに関するコンセンサス. 日検査血液会誌. 2016 ; 17 : 149.
 
P.24 掲載の参考文献
1) 朝倉英策. 活性化部分トロンボプラスチン時間 (APTT). In : 朝倉英策, 編. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. p.35-7.
 
2) 小山薫. Hemodialysis, CVVH時の抗凝固療法. In : 武田純三, 編. 血液凝固, 抗凝固, 線溶系がわかる本. 第2版. 東京 : 真興交易医書出版部 ; 2015. p.186-90.
 
3) 日本循環器学会, 他. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版) 2015/10/7 更新版 : http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (2018年5月22日確認)
 
4) 山崎哲, 他. APTT検査およびループスアンチコアグラント検査の標準化. 血栓止血誌. 2016 ; 27 : 636-43.
 
5) 吉賀正亨, 他. D-dimer異常高値を認めた悪性黒色腫の一例. 日検血会誌. 2007 ; 8 : 307-11.
 
6) DIC診断基準作成委員会, 他. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血誌. 2017 ; 28 : 369-81.
 
P.29 掲載の参考文献
1) 家子正裕, 他. 凝固検査検体取扱いに関するコンセンサス. 日検血会誌. 2016 ; 17 : 149.
 
2) Adock DM, et al. Effect of 3.2% vs. 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997 ; 107 : 105.
 
3) 渡邊卓, 編. JCCLSの標準採血法ガイドライン (GP4-A2). 日本臨床検査標準協議会 ; 2011. p.19.
 
4) Approved guideline 5th ed H21-A5. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays ; Approved Guileline-Fith Edition. http://shopping.netsuite.com/s.nl/c.1253739/it.A/id.318/.f.
 
5) 吉田美香, 他. 全血の保存条件および保存時間がPT測定に及ぼす影響についての検討. 日検血会誌. 2013 ; 14 : 267.
 
6) Yoshida M, et al. Is plasma separated from blood by double centrifugation useful for determination of lupus anticoagulant? Thromb Haemost. 2011 ; 9 (Suppl. 2) : 879.
 
7) Mackie I, et al. Guideline on the laboratory aspects of assay used in haemostasis and thrombosis. Int J Clin Hematol. 2013 : 35 : 1.
 
8) Favaloro EJ, et al. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. Am J Clin Pathol. 2004 ; 122 : 686.
PubMed
P.35 掲載の参考文献
1) Miyata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009 ; 124 : 14.
PubMed
2) Miyawaki Y, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012 ; 366 : 2390.
PubMed
3) Delvaeye M, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009 ; 361 : 345.
PubMed
4) 田嶌優子, 他. プラスミノーゲン栃木変異ホモ接合体マウスの血栓傾向の解析. 血栓止血会誌. 2013 ; 24 : 194.
 
5) Suzuki A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha) -Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010 ; 285 : 13444.
PubMed
P.41 掲載の参考文献
1) Iwaki T, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost. 2011 ; 9 : 1200.
PubMed
2) 森下英理子. 後天性von Willebrand病, 後天性第XIII因子欠乏症. In : 血管症候群 (第2版) -その他の血液疾患を含めて-II. 別冊日本臨床 新領域別症候群シリーズ No.22. 2013. p.587.
 
3) Baca V, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome : report of two cases and review of the literature. Am J Hematol. 2002 ; 71 : 200.
PubMed
4) 森下英理子. 後天性第V因子インヒビター. In : 血管症候群 (第2版) -その他の血液疾患を含めて-II. 別冊日本臨床 新領域別症候群シリーズ No.22. 2013. p.584.
 
P.45 掲載の参考文献
1) PT (PT-INR) とは? 正常値, ワーファリン, ビタミンK欠乏症. http://www.3nai.jp/weblog/entry/23566.html
 
2) Gudmundsdottir BR, et al. Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. Thromb Res. 2012 ; 130 : 674.
 
3) Onundarson PT, et al. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation : a single centre, double-blind, randomised, non-inferiority trial. Lancet Haematol. 2015 ; 2 : e231.
PubMed
4) Jonsson PI, et al. During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time. J Thromb Haemost. 2017 ; 15 : 131.
 
P.49 掲載の参考文献
1) 血液・呼吸器内科のお役立ち情報 : APTTとは/ヘパリンのモニタリングか. http://www.3nai.jp/weblog/entry/23570.html
 
P.53 掲載の参考文献
1) de Groot PG, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005 : 3 : 1993.
PubMed
2) Smock KJ, et al. Laboratory identification of lupus anticoagulants. Am J Hematol. 2009 ; 84 : 440.
PubMed
3) 家子正裕. ループスアンチコアグラントとクロスミキシング試験. In : 朝倉英策, 編. 臨床に直結する血栓止血学. 第1版. 東京 : 中外医学社 ; 2013. p.38.
 
4) 家子正裕, 他. 凝固検査検体取扱いに関するコンセンサス. 日検血会誌. 2016 : 17 : 149.
 
5) 家子正裕. クロスミキシング試験を臨床に活かすには. 医療と検査機器・試薬. 2012 : 36 : 867.
 
6) 家子正裕, 他. 交差混合試験における混合比率およびコントロール血漿に関する検討-コアプレスタミキシングテスト研究会における結果報告 (第1報) -. 日検血会誌. 2012 : 12 : 312.
 
P.55 掲載の参考文献
1) Kasper CK, et al. A more uniform measurement of factor VIII inhibitor. Thromb Diathes Haemorrh. 1975 ; 34 : 869.
 
2) Verbruggen B, et al. The Nijmegen modification of the Bethesda assay for factor VIII : C inhibitors : Improved specificity and reliability. Thromb Haemost. 1995 ; 73 : 247.
PubMed
3) 田中一郎, 他. 血友病インヒビター. 血栓止血誌. 2000 ; 11 : 559.
 
P.59 掲載の参考文献
1) 一瀬白帝, 他. 止血機構と血栓症-オーバービュー. In : 一瀬白帝, 他編, 新・血栓止血血管学 血管と血小板. 京都 : 金芳堂 ; 2015. p.1.
 
2) Souri M, et al. Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2B2 assembly and steal FXIII-A from native FXIII-A2B2. J Thromb Haemost. 2015 ; 13 : 802.
 
3) Uchida E, et al. Autoimmune hemorrhaphilia resulting from autoantibody against the A Subunit of Factor XIII. Intern Med. 2015 ; 54 : 2383.
PubMed
4) Tsuda M, et al. Spontaneous splenic rupture accompanied by hepatic arterial dissection in a patient with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Haemophilia. 2016 ; 22 : e314.
 
5) Kojima M, et al. (Erratum to:) Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies. Int J Hematol. 2016 ; 103 : 341.
 
6) Osaki T, et al. Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90% of cases with autoimmune haemorrhaphilia XIII/13. Thromb Haemost. 2015 ; 113 : 1347.
 
7) Ogawa Y, et al. Successful management of a patient with autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies complicated by pulmonary thromboembolism. Acta Haematol. 2017 ; 137 : 141.
PubMed
8) Ichinose A. Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies : A summary of 93 patients. Blood Rev. 2017 ; 31 : 37.
 
9) 自己免疫性出血病FXIII/13 日本血栓止血学会診療ガイド作成委員会 (一瀬白帝, 他). 自己免疫性出血病FXIII/13 診療ガイド. 血栓止血誌. 2017 ; 28 : 393.
 
P.62 掲載の参考文献
1) Kadohira Y, et al. A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors. Int J Hematol. 2018 ; 108 : 145.
PubMed
2) Franchini M, et al. Acquired factor V inhibitors : a systematic review. J Thromb Thrombolysis. 2011 ; 314 : 449.
 
3) Ang AL, et al. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost. 2009 ; 101 : 852.
PubMed
4) 一瀬白帝. わが国における自己免疫性凝固因子欠乏症の実態と診療ガイド. 血栓止血誌. 2018 ; 29 : 251.
 
5) Ashizawa, M, et al. Acquired factor V inhibitor associated with life-threatening bleeding and a mixing test result that indicated coagulation factor deficiency. Hematology. 2013 ; 18 : 300.
 
P.65 掲載の参考文献
1) Kadohira Y, et al. A discrepancy between PT and HPT results is useful for diagnosis of acquired factor V inhibitors. Int J Hematol. 2018 ; 108 : 145.
PubMed
P.67 掲載の参考文献
1) Lindahl TL, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011 ; 105 : 371.
PubMed
P.70 掲載の参考文献
1) 窓岩清治. 止血・抗凝固機序. In : 日本血液学会, 編. 血液専門医テキスト. 東京 : 南江堂 ; 2011. p.19.
 
2) 医薬品医療機器総合機構 医療用医薬品の添付文書情報. http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html
 
P.76 掲載の参考文献
1) 門平靖子, 他. DOAC療法が先天性血栓性素因に及ぼす影響. 血栓止血誌. 2018 ; 29 : 10.
 
2) Tsuda T, et al. New quantitative total protein S-assay system for diagnosing protein S type II deficiency : clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis. 2012 ; 23 : 56.
PubMed
3) Sekiya A, et al. Thrombosis Prediction Based on Reference Ranges of Coagulation-Related Markers in Different Stages of Pregnancy. Clin Appl Thromb Hemost. 2017 ; 23 : 844.
PubMed
4) Kimura R, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006 ; 4 : 2010.
 
P.81 掲載の参考文献
1) 門平靖子, 他. DOAC療法が先天性血栓性素因に及ぼす影響. 血栓止血誌. 2018 ; 29 : 20.
 
2) Lindahl TL, et al : Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effect of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011 ; 105 : 371.
 
3) Hillarp A, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011 ; 9 : 133.
PubMed
P.84 掲載の参考文献
1) The Human Gene Mutation Database. www.hgmd.cf.ac.uk/
 
2) 平成29年4月1日施行の指定難病 (厚生労働省). http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000085261.html
 
3) ヒトゲノム・遺伝子解析研究に関する倫理指針 (厚生労働省). http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/genome/0504sisin.html
 
P.87 掲載の参考文献
1) Kinoshita S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005 ; 38 : 908.
PubMed
2) Ikejiri M, et al. The association of protein S tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol. 2010 ; 92 : 302.
PubMed
3) Kimura R, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006 ; 107 : 1737.
PubMed
4) Miyata T, et al. More on : racial differences in venous thromboembolism. J Thromb Haemost. 2012 ; 10 : 319.
PubMed
5) Tsuda T, et al. New quantitative total protein S-assay system for diagnosing protein S type II deficiency : clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis. 2012 ; 23 : 56.
PubMed
6) Maruyama K, et al. ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism. PLoS One. 2015 ; 10 : e0133196.
PubMed
7) Kimura R, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006 ; 4 : 2010.
 
P.94 掲載の参考文献
1) 古賀震. FDPとDダイマー. 救急集中治療. 2008 ; 20 : 547.
 
2) 片桐尚子, 他. 分子マーカーの標準化, In : 渡辺清明, 他編. 臨床病理レビュー特集 第130号. 東京 : 臨床病理刊行会 ; 2004. p.87.
 
3) 朝倉英策. 1. DIC : 治療の考え方とその進歩. 日検血会誌. 2003 ; 4 : 27.
 
4) 青木延雄, 他. DIC診断基準の「診断のための補助的検査成績, 所見」の項の改訂について, 厚生省特定疾患血液凝固異常症調査研究班 : 昭和62年度研究報告書. 1988. p.37.
 
5) 和田英夫, 他. DICの診断基準. 臨床病理. 2002 ; 50 : 273.
Medical*Online
6) 川合陽子. FDP, FDP-Dダイマー臨床検査. 1996 ; 40 (増刊号) : 147.
 
7) 家子正裕. 可溶性フィブリンモノマー複合体の測定試薬の特性. 検査と技術. 2008 ; 36 : 430.
 
8) 古賀震. 血栓形成と生命予後の新しいマーカー. 臨床病理. 2004 ; 52 : 355.
Medical*Online
9) 古賀震. 最近注目されている凝固線溶分子マーカー. 救急医学. 2004 ; 28 : 823.
 
10) 古賀震. DIC～とびらを拓く第三世代へ. 臨床病理レビュー. 2011 ; 147 : 71.
 
P.97 掲載の参考文献
1) Sneeboer MMS, et al. Prothrombotic state in patients with severe and prednisolone-dependent asthma. J Allergy Clin Immunol. 2016 ; 137 : 1727.
 
2) Jiang H, et al. Plasminogen activator inhibitor-1 in depression : results from animal and clinical studies. Sci Rep. 2016 ; 6 : 30464.
PubMed
P.100 掲載の参考文献
1) 日本血栓止血学会学術標準化委員会DIC部会. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 2009 ; 20 : 77.
 
2) 日本血栓止血学会. http://www.jsth.org/glossary_detail/?id=195
 
3) 日本血栓止血学会. http://www.jsth.org/guideline/
 
P.104 掲載の参考文献
1) Linscheid P, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells : a novel product of human adipose tissue. Endocrinology. 2003 ; 144 : 5578.
 
2) Harbarth S, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001 ; 164 : 396.
PubMed
3) Georgopoulou AP, et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011 ; 26 : 331.
 
4) Bouadma L, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial) : a multicentre randomised controlled trial. Lancet. 2010 ; 375 : 463.
 
5) Rhodes A, et al. Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock : 2016. Intensive Care Med. 2017 ; 43 : 304.
PubMed
6) Bloos F, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation : a multicenter observational study. Crit Care. 2011 ; 15 : R88.
PubMed
7) Yu H, et al. Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis. Am J Emerg Med. 2017 ; 35 : 835.
PubMed
8) Shozushima T, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011 ; 17 : 764.
PubMed
9) Endo S, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012 ; 18 : 891.
 
10) Vodnik T, et al. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med. 2013 ; 51 : 2053.
PubMed
11) Ulla M, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department : a multicenter prospective study. Crit Care. 2013 ; 17 : R168.
PubMed
12) Masson S, et al ; ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis : data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014 ; 18 : R6.
 
13) Topcuoglu S, et al. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Fetal Neonatal Med. 2015 : 10 : 1.
 
14) Mussap M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS. Clin Chim Acta. 2015 ; 451 : 65.
PubMed
15) Iskandar A, et al. GREAT Network. Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis. J Matern Fetal Neonatal Med. 2018 ; 9 : 1.
 
16) The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). J Intensive Care. 2018 ; 6 : 7.
PubMed
P.106 掲載の参考文献
1) 岡本好司, 他. 敗血症DICの発症機序と治療 HMGB1とトロンボモデュリン (Thrombomodulin). 日外感染症会誌. 2010 ; 7 : 149.
Medical*Online
2) Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999 ; 285 : 248.
PubMed
3) Hatada T, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005 ; 94 : 975.
PubMed
P.109 掲載の参考文献
1) Gordon EM, et al. Reduced titers of Hageman factor (factor XII) in Orientals. Ann Inter Med. 1981 ; 95 : 697.
 
2) Miyawaki Y, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012 ; 366 : 2390.
PubMed
3) Simioni P, et al. X-linked thrombophilia with mutant factor IX (factor IX Padua). N Engl J Med. 2009 ; 361 : 1671.
PubMed
P.112 掲載の参考文献
1) Joachim J, et al. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015 ; 94 Suppl. 77 : 38.
 
2) Wayne L, et al. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003 ; 120 : 34.
 
3) Dorothy M, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013 ; 139 : 102.
 
4) Tichelaar V, et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII : C assays. Thromb Haemost. 2011 ; 106 : 990.
PubMed
P.118 掲載の参考文献
1) 前川正. 溶血性貧血分科会. 厚生省特定疾患特発性造血障害調査研究班研究業績報告書, 厚生省特定疾患特発性造血障害調査研究班. 1990. p.64.
 
2) 日本検査血液学会標準化委員会血液形態検査標準化小委員会ホームページ. http://www.jslh-sc.com/
 
3) Zini G, et al ; International Council for Standardization in Haematology (ICSH). ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012 ; 34 : 107.
PubMed
4) 渡部俊幸. 破砕赤血球の識別基準. 臨床検査. 2016 ; 60 : 1410.
 
5) Lesesve JF, et al. Fragmented red blood cells automated measurement is a useful parameter to exclude schistocytes on the blood film. Int J Lab Hematol. 2012 ; 34 : 566.
PubMed
6) 池亀彰茂, 他. %Micro (ADVIA120) による破砕赤血球のスクリーニング. 日検血会誌. 2011 ; 12 : 202.
 
7) 今田昌秀, 他. 総合血液学検査装置 ADVIA2120 (RBC Matrix) を用いた破砕赤血球の検出. 日検血会誌. 2012 ; 13 : 49.
 
8) 関根久実, 他. 破砕赤血球出現に及ぼす貧血の影響と種々の問題点. 医学検査. 2005 ; 54 : 220.
Medical*Online
P.121 掲載の参考文献
1) Biino G, et al. Age and sex-related variations in platelet count in Italy : a proposal of reference ranges based on 40987 subjects' data. PLoS One 2013 ; 8 : e54289.
PubMed
2) Greer J, et al. Wintrobe's clinical hematology. 13th ed. Philadelphia : Lippincott Williams & Wilkins ; 2014.
 
3) Balduini CL, et al. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost. 2013 ; 11 : 1006.
PubMed
4) 冨山佳昭. 特発性血小板減少性紫斑病 (ITP). In : 金倉譲, 冨山佳昭, 編. よくわかる血栓・止血異常の診療. 東京 : 中山書店 ; 2014. p.80.
 
5) 藤村吉博. 血栓性血小板減少性紫斑病. 臨床血液. 2012 ; 53 : 185.
 
6) George JN, et al. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 ; 371 : 1847.
PubMed
P.125 掲載の参考文献
1) 高見昭良. 幼若血小板比率の臨床意義. 日血栓止血会誌. 2010 ; 21 : 547.
 
2) Khandekar MM, et al. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction : an Indian scenario. J Clin Pathol. 2006 ; 59 : 146.
PubMed
3) Klovaite J, et al. High platelet volume and increased risk of myocardial infarction : 39,531 participants from the general population. J Thromb Haemost. 2011 ; 9 : 49.
PubMed
4) Slavka G, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011 ; 31 : 1215.
PubMed
5) Panova-Noeva M, et al. Sex-specific differences in genetic and nongenetic determinants of mean platelet volume : results from the Gutenberg Health Study. Blood. 2016 ; 127 : 251.
PubMed
6) Yin JB, et al. Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases. Sci Rep. 2018 ; 8 : 6014.
PubMed
7) Yun ZY, et al. Lower mean platelet volume predicts poor prognosis in renal cell carcinoma. Sci Rep. 2017 ; 7 : 6700.
PubMed
8) Gang L, et al. Association between mean platelet volume and hypertension incidence. Hypertens Res. 2017 ; 40 : 779.
PubMed
P.133 掲載の参考文献
1) 高見昭良. 悪性腫瘍に合併する血栓止血異常 網血小板測定の臨床意義. 日検査血液会誌. 2016 ; 17 : 422-6.
 
2) Takami A, et al. Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007 ; 39 : 501.
PubMed
3) Sugimori N, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome : a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol. 2009 ; 82 : 54.
PubMed
4) Kurahashi H, et al. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction. Int J Hematol. 2018 ; 107 : 105.
 
5) Miyazaki K, et al. Immature platelet fraction measurement is influenced by platelet size and is a useful parameter for discrimination of macrothrombocytopenia. Hematology. 2015 ; 20 : 587.
PubMed
P.136 掲載の参考文献
1) Ng C, et al. Diagnostic approach to von Willebrand disease. Blood. 2015 ; 125 : 2029.
PubMed
P.138 掲載の参考文献
1) Scully M, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 ; 15 : 312.
PubMed
2) 松本雅則, 他. 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液. 2017 ; 58 : 271.
 
P.141 掲載の参考文献
1) 宮田茂樹. ヘパリン起因性血小板減少症における最新の知見. 血栓止血誌. 2012 ; 23 : 362.
 
2) Nagler M, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia : a systematic review and meta-analysis. Blood. 2016 ; 127 : 546.
PubMed
P.144 掲載の参考文献
1) Lin JJ, et al. Increased serum thrombomodulin level is associated with disease severity and mortality in pediatric sepsis. PLoS One. 2017 ; 12 : e0182324.
PubMed
2) Sane M, et al. Plasma levels of haemostatic factors in patients with pulmonary embolism on admission and seven months later. Int J Lab Hematol. 2018 ; 40 : 66.
PubMed
P.147 掲載の参考文献
1) 本木由香里, 他. ELISAによる抗リン脂質抗体測定の標準化に向けて. 血栓止血誌. 2016 ; 27 : 644.
 
2) 野島順三. 抗リン脂質抗体症候群の検査診断に向けた新展開. 日検血会誌. 2011 ; 12 : 399.
 
3) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295.
 
4) Devreese K, et al. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem. 2010 ; 56 : 930.
PubMed
5) Giannakopoulos B, et al. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 ; 68 : 1033.
 
P.150 掲載の参考文献
1) Pengo V, et al. Antiphospholipid syndrome : antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015 ; 13 : 782.
 
2) Banzato A, et al. Antibodies to Domain I of beta (2) glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res. 2011 ; 128 : 583.
 
3) de Laat B, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis : an international multicenter study. J Thromb Haemost. 2009 ; 7 : 1767.
 
4) Atsumi T, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 ; 43 : 1982.
PubMed
5) Sciascia S, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014 ; 111 : 354.
PubMed
6) Vlagea A, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost. 2013 ; 19 : 289.
 
7) Zigon P, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol. 2013 ; 724592.
PubMed
8) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295.
 
9) Devreese K, et al. Laboratory diagnosis of the antiphospholipid syndrome : a plethora of obstacles to overcome. Eur J Haematol. 2009 ; 83 : 1.
PubMed
10) Nakamura H, et al. First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice : a combination of anti-beta2-glycoprotein I Domain I and anti-phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res (Hoboken). 2018 ; 70 : 627.
 
P.153 掲載の参考文献
1) Marti-Carvajal AJ, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013 ; (1) : CD006612.
 
P.156 掲載の参考文献
1) 岡本好司. 止血・凝固・線溶系. In : 武藤徹一郎, 他, 編. 新臨床外科学 第4版. 東京 : 医学書院 ; 2006. p.71.
 

3章 出血性疾患

P.162 掲載の参考文献
1) 宮川義隆. 本邦における特発性血小板減少性紫斑病の診療. 臨床血液. 2013 ; 54 : 350,
 
2) 藤村欣吾, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液. 2012 ; 53 : 433.
 
3) 宮川義隆. ITPの新しい治療薬. 血栓止血誌. 2010 ; 21 : 262.
 
4) 日本小児血液学会ITP委員会, 他. 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小血会誌. 2004 ; 18 : 210.
 
5) 宮川義隆. 国内外のITPガイドラインの特徴と課題. In : 高久史麿, 他, 編. Annual Review血液 2013. 東京 : 中外医学社 ; 2013. p.195.
 
P.167 掲載の参考文献
1) 宮川義隆, 他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液. 2014 ; 55 : 934.
 
2) Gernsheimer T, et al. How I treat thrombocytopenia in pregnancy. Blood. 2013 ; 121 : 38.
 
3) 藤村欣吾, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液. 2012 ; 53 : 433.
 
4) British Committee for Standard in Haematology General Haematology Task Force : Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol. 2003 ; 120 : 574.
PubMed
5) Provan D, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 ; 115 : 168
PubMed
6) Neunert C, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 ; 117 : 4190.
PubMed
P.175 掲載の参考文献
1) 藤井輝久, 他. インヒビターのない血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌. 2013 ; 24 : 619
 
2) Manco-Johnson, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 ; 357 : 535.
PubMed
3) Blanchetted VS, et al. Definitions in hemophilia : communication from the SSC of the ISTH. J Thromb Haemost. 2014 ; 12 : 1935.
 
4) Manco-Johnson MJ, et al. Effect of late prophylaxis in hemophilia on joint status. J Thromb Haemost. 2017 ; 15 : 1.
 
5) 酒井道生, 他. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌. 2013 ; 24 : 640.
 
6) Hay CRM, et al. The principal results of the International Immune Tolerance Study : a randomized dose comparison. Blood. 2012 ; 119 : 1335.
PubMed
7) Shima M, et al. Factor VIII mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016 ; 374 : 2044.
PubMed
8) Oldenburg J, et al. Emicizumab prophylaxis in haemophilia A with inhibitors. N Engl J Med. 2017 ; 377 : 809.
PubMed
P.180 掲載の参考文献
1) Den Uijl IE, et al. Clinical severity of haemophilia A : does the classification of the 1950s still stand? Haemophilia. 2011 ; 17 : 849.
PubMed
2) Knobe K, et al. Haemophilia and joint disease : pathophysiology, evaluation, and management. J Comorb. 2011 ; 1 : 51.
PubMed
3) Blanchette VS, et al. Definitions in hemophilia : communication from the SSC of the ISTH. J Thromb Haemost. 2014 ; 12 : 1935.
PubMed
4) Pettersson H, et al. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res. 1980 ; 149 : 153.
PubMed
5) Arnold WD, et al. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am. 1977 ; 59 : 287.
PubMed
6) Lundin B, et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia. 2012 ; 18 : 962.
 
7) Martinoli C, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost. 2013 ; 109 : 1170.
PubMed
P.184 掲載の参考文献
1) Nathwani AC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 ; 365 : 2357.
PubMed
2) Nathwani AC, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014 ; 371 : 1994.
PubMed
3) George LA, et al. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 ; 377 : 2215.
PubMed
4) Rangarajan S, et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017 ; 377 : 2519.
PubMed
5) Ohmori T, et al. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep. 2017 ; 7 : 4159.
PubMed
P.192 掲載の参考文献
1) 滝正志, 他. 血液凝固異常症全国調査, 平成29年度報告書 (財団法人エイズ予防財団). 2017.
 
2) Peyvandi F, et al. Rare coagulation deficiencies. Haemophilia. 2002 ; 8 : 308.
PubMed
3) Mannucci PM, et al. Recessively inherited coagulation disorders. Blood. 2004 ; 104 : 1243.
PubMed
4) Peyvandi F, et al. Rare bleeding disorders. Haemophilia, 2012 ; 18 : 148.
PubMed
5) Mumford AD, et al. Guidelines for the diagnosis and management of the rare coagulation disorders ; a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Hamatol. 2014 ; 167 : 304.
 
P.195 掲載の参考文献
1) Herrmann FH, et al. Factor X deficiency : clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia. 2006 ; 12 : 479.
PubMed
2) Cooper DN, et al. Inherited factor X deficiency : Molecular genetics and pathophysiology. Thromb Haemost. 1997 ; 78 : 161.
PubMed
3) 篠澤圭子, 他. 凝固因子欠乏症の疫学, 遺伝子解析. 日内会誌. 2009 ; 98 : 1599.
 
4) 長江千愛, 他. その他の先天性凝固因子欠損症の診断と治療. 血栓止血誌. 2010 ; 21 : 297.
 
P.200 掲載の参考文献
1) Lavin M, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017 ; 130 : 2344.
PubMed
2) Castaman G, et al. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013 ; 98 : 667.
PubMed
P.206 掲載の参考文献
1) Asahina T, et al. Congenital blood coagulation factor XIII deficiency and successful deliveries : a review of the literature. Obstet Gynecol Surv. 2007 ; 62 : 255.
PubMed
2) Kobayashi T, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol. 2000 ; 109 : 364.
PubMed
3) Catanzarite VA, et al. Pregnancies in a patient with congenital absence of prothrombin activity : case report. Am J Perinatol. 1997 ; 14 : 135.
 
4) Bolton-Maggs PH, et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Center Doctors' Organization. Haemophilia. 2004 ; 10 : 593.
PubMed
5) Romagnolo C, et al. Severe factor X deficiency in pregnancy : case report and review of the literature. Haemophilia. 2004 ; 10 : 665.
PubMed
6) Girolami A, et al. Pregnancy and oral contraceptives in factor V deficiency : a study of 22 patients (five homozygotes and 17 heterozygotes) and review of literature. Haemophilia. 2005 ; 11 : 26.
PubMed
7) 高宮脩, 他. 先天性第VII因子欠乏症. 血栓止血誌. 2001 ; 12 : 320.
 
8) Myers B, et al. Pregnancy outcome in Factor XI deficiency : incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG. 2007 ; 114 : 643.
PubMed
9) Matsuura T, et al. Is factor XII deficiency related to recurrent miscarriage? Seminars in Thrombosis and Hemostasis. 2001 ; 27 : 115.
PubMed
10) Kadir RA, et al. The obstetric experience of carriers of haemophilia. BJOG. 1997 ; 104 : 803.
 
P.212 掲載の参考文献
1) 嶋緑倫, 他. 本邦における血液凝固後天性インヒビターの実態. 血栓止血誌. 2003 ; 14 : 107.
 
2) 田中一郎, 他. わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 血栓止血誌. 2008 ; 19 : 140.
 
3) 野上恵嗣. 後天性凝固因子インヒビター. 臨床血液. 2015 ; 56 : 160.
 
4) 酒井道生, 他. 後天性血友病A診療ガイドライン 2017年改訂版. 血栓止血誌. 2017 ; 28 : 710.
 
5) Collins PW, et al. Advances in the understanding of acquired haemophilia A : implications for clinical practice. Br J Haematol. 2010 ; 148 : 183.
PubMed
6) 野上恵嗣. 包括的凝固検査を用いた血友病診療の発展. 血栓止血誌 2017 ; 28 : 451.
 
P.220 掲載の参考文献
1) Mital A. Acquired von Willebrand syndrome. Adv Clin Exp Med. 2016 ; 25 : 1337.
 
2) Stuijver DJF, et al. Acquired von Willebrand syndrome in patients with overt hypothyroidism : a prospective cohort study. Haemophilia. 2013 ; 20 : 326.
 
3) 堀内久徳, 他. 循環器疾患随伴後天性フォンウィルブランド症候群の臨床的インパクト. 血栓止血誌. 2016 ; 27 : 316.
 
4) Matsumoto M, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb. 2005 ; 34 : 35.
PubMed
5) Tamura T, et al. Unexpectedly high prevalence of acquired von Willebrand syndrome in patients with severe aortic stenosis as evaluated with a novel large multimer index. J Atherosclerosis Thrombosis. 2015 ; 22 : 1115.
 
6) Johannes K, et al. Early diagnosis of acquired von Willebrand syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb. 2015 ; 22 : 265.
 
7) Sakatsume K, et al. Association between severity of acquired von Willebrand syndrome and gastrointestinal bleeding after continuous flow left ventricular assist device implantation. Eur J Cardio-Thorac Surg. 2018 in press (doi : 10.1093/ejcts/ezy172).
 
P.227 掲載の参考文献
1) Ichinose A. Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies : A summary of 93 patients. Blood Rev. 2017 ; 31 : 37.
 
2) 自己免疫性出血病FXIII/13 日本血栓止血学会診療ガイド作成委員会 (一瀬白帝, 他). 自己免疫性出血病FXIII/13 診療ガイド. 血栓止血誌. 2017 ; 28 : 393.
 
3) 指定難病288自己免疫性凝固因子欠乏症. 厚生労働省. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000079293.html
 
4) Ichinose A, et al. Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiency. Thromb Haemost. 2016 ; 116 : 772.
 
5) 自己免疫性出血病FXIII/13 日本血栓止血学会診断基準作成委員会 (一瀬白帝, 他). 自己免疫性出血病FXIII/13診断ガイド. 血栓止血誌. 2015 ; 26 : 658.
 
6) Souri M, et al. Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2B2 assembly and steal FXIII-A from native FXIII-A2B2. J Thromb Haemost. 2015 ; 13 : 802.
 
7) Osaki T, et al. Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90% of cases with autoimmune haemorrhaphilia XIII/13. Thromb Haemost. 2015 ; 113 : 1347.
 
8) Kojima M, et al. (Erratum to:) Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies. Int J Hematol. 2016 ; 103 : 341.
 
9) Ogawa Y, et al. Complete remission achieved by steroid pulse therapy following rituximab treatment in a case with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Thromb Haemost. 2014 ; 112 : 831.
 
10) Kotake T, et al. Report of a patient with chronic intractable autoimmune hemorrhaphilia due to anti-factor XIII/13 antibodies who died of hemorrhage after sustained clinical remission for 3 years. Int J Hematol. 2015 ; 101 : 598.
PubMed
P.232 掲載の参考文献
1) 厚生労働省. 日本人の食事摂取基準 (2015年度版).
 
2) Sutor AH. Vitamin K deficiency bleeding in infancy : a status report. In : Sutor AH, et al, eds. Vitamin K in infancy. Stuttgart : Schattaner ; 1995. p.3.
 
3) 白幡聡, 他. 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌. 2011 ; 115 : 705.
 
4) 森美貴, 他. 特集 : 血栓止血の臨床-研修医のために 止血薬, 抗線溶薬の適応と使用法 2. 凝固促進薬 (ビタミンK, プロタミン). 血栓止血誌. 2009 ; 20 : 281.
 
P.240 掲載の参考文献
1) Sivapalaratnam S, et al. Diagnosis of inherited bleeding disorders in the genomic era. Br J Haematol. 2017 ; 179 : 363.
PubMed
2) Lentaigne C, et al. Inherited platelet disorders : toward DNA-based diagnosis. Blood. 2016 ; 127 : 2814.
PubMed
3) Gresele P, et al. Diagnosis of suspected inherited platelet function disorders : results of a worldwide survey. J Thromb Haemost. 2014 ; 12 : 1562.
PubMed
4) Gresele P, et al. Diagnosis of inherited platelet function disorders : guidance from the SSC of the ISTH. J Thromb Haemost. 2015 ; 13 : 314.
PubMed
5) 笹原洋二. ITPと鑑別が必要な小型・正常大の血小板を有する遺伝性血小板減少症. 日小児血がん会誌. 2015 ; 52 : 311.
Medical*Online
6) Gresele P, et al. Laboratory diagnosis of clinically relevant platelet function disorders. Int J Lab Hematol. 2018 ; 40 Suppl 1 : 34.
 
7) 加藤恒. 血小板機能異常症の診断 まれな出血傾向を見逃さないために. 臨床血液. 2016 ; 57 : 2159.
 
8) Cattaneo M, et al. Recommendations for the standardization of light transmission aggregometry : a consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013 ; 11 : 1183.
 
9) Dovlatova N. Current status and future prospects for platelet function testing in the diagnosis of inherited bleeding disorders. Br J Haematol. 2015 ; 170 : 150.
PubMed
10) Freson K, et al. High-throughput sequencing approaches for diagnosing hereditary bleeding and platelet disorders. J Thromb Haemost. 2017 ; 15 : 1262.
PubMed
P.246 掲載の参考文献
1) 國島伸治. 先天性巨大血小板症の鑑別診断. 血栓止血誌. 2011 ; 22 : 100.
 
2) 國島伸治. 先天性血小板減少症の診断と分子病態. 臨床血液. 2014 ; 55 : 882.
 
3) 國島伸治. 血小板造血関連遺伝子の異常に基づく疾患. 血栓止血誌. 2016 ; 27 : 538.
 
P.251 掲載の参考文献
1) 金子誠. 血小板機能異常症の診断と対応. In : 日本血栓止血学会, 編. わかりやすい血栓と止血の臨床. 東京 : 南江堂 ; 2011. p.48.
 
2) 大森司. 先天性血小板減少症・機能異常症. In : 日本血液学会, 編. 血液専門医テキスト. 東京 : 南江堂 ; 2011. p.383.
 
3) Rao AK. Aquired qualitative platelet defects. In : Colman RW, et al. Editors. Hemostasis and Thrombosis : basic principles and clinical practice-5th edition. PA : Lippincott Williams & Wilkins ; 2006. p.1045.
 
4) 松下正. 処置・手術時の抗凝固薬, 抗血小板薬の扱い. Medicina. 2011 ; 48 : 1798.
 
P.256 掲載の参考文献
1) Williams RC. Immune complexes in clinical and experimental medicine. Massachustts : Harvard University Press ; 1980.
 
2) 依藤寿, 他. 井村裕夫, 他編. 最新内科学大系 21, 血小板・凝固・線溶異常 (血液造血器疾患 4). 東京 : 中山書店 ; 1992. p.296.
 
3) Foster BJ, et al. Effective therapy for Henoch-Schonlein purpura nephritis with prednisone and azathioprine : A clinical and histopathologic study. J Pediatr. 2000 ; 136 : 370.
PubMed
P.261 掲載の参考文献
1) 垣下榮三. 血管壁障害によるもの. In : 黒川清, 他編. EBM現代内科学. 京都 : 金芳堂 ; 1997. p.1540.
 
2) Ratnam KV, et al. Purpura simplex (inflammatory purpura without vasculitis) : a clinicopathologic study of 174 cases. J Am Acad Dermatol. 1991 ; 25 : 642.
 
3) 西山茂夫. 皮膚病アトラス 4. 東京 : 文光堂 ; 1997. p.82.
 
4) Haboubi NY, et al. Zinc deficiency in senile purpura. J Clin Pathol. 1985 ; 38 : 1189.
 
5) 清水正行. 福代良一, 他編. 皮膚科診療治療大系 3. 東京 : 講談社 ; 1985. p.39.
 
P.271 掲載の参考文献
1) 遺伝性出血性末梢血管拡張症・診療ガイドライン作成委員会. 委員長塩谷隆信, 編. 遺伝性出血性末梢血管拡張症 (HHT) の診療マニュアル (増補版). 東京 : 中外医学社 ; 2015.
 
2) 塩谷隆信. オスラー病 (遺伝性出血性末梢血管拡張症). 呼吸. 2014 ; 33 : 171.
 
3) Wintrobe MM. Hereditary hemorrhagic telangiectasia. In : Lee GR, et al, ed. Wintrobe's Clinical Hematology. Vol.2. 9th ed. Philadelphia and London : Lee & Febieger ; 1993. p.1379.
 
4) Dakeishi M, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia. Hum Mutat. 2002 ; 19 : 140.
 
5) Komiyama M, et al. Hereditary hemorrhagic telangiectasia in Japan. J Hum Genet. 2014 ; 59 : 37-41.
PubMed
6) Shovlin CL, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000 ; 91 : 66.
PubMed
7) Faughnan ME, et al. International guidelines for diagnostis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2011 ; 48 : 73.
 
8) de Gussem EM et al. Life expertancy of parents with hereditary haemorrhagic telangiectasia. Orphanet J Rare Dis. 2016 ; 11 : 46.
 
9) Shioya T, et al. Comparison of PAVMs associated or not associated with hereditary hemorrhagic telangiectasia in the Japanese population. Respiratory Investigation 2015 ; 53 : 300.
PubMed
10) 塩谷隆信, 他. 家族性肺動静脈奇形を合併した遺伝性出血性末梢血管拡張症 (Osler病). 日内会誌. 2010 ; 99 : 2529.
 
P.276 掲載の参考文献
1) Sucker C, et al. Amyloidosis and bleeding : pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006 ; 47 : 947.
PubMed
2) Choufani EB, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis : incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001 ; 97 : 1885.
PubMed
3) Thompson CA, et al. Systemic AL amyloidosis with acquired factor X deficiency : A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010 ; 85 : 171.
PubMed
4) Zangari M, et al, Hemostatic dysfunction in paraproteinemias and amyloidosis. Sem Thromb Hemost. 2007 ; 33 : 339.
 
5) Suzuki K. Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol. 2012 ; 16 : 659.
PubMed
P.280 掲載の参考文献
1) Coughlin PB. Antiplasmin : the forgotten serpin? FEBS J. 2005 ; 272 : 4852.
PubMed
2) Schaller J, et al. The plasmin-antiplasmin system : structural and functional aspects. Cell Mol Life Sci. 2011 ; 68 : 785.
PubMed
3) 内場光浩. DIC ; 凝固系制御と線溶系制御の破綻. 日検血会誌. 2018 ; 19 : 1.
 
P.284 掲載の参考文献
1) Jennete JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Arthritis Rheum. 2013 ; 65 : 1.
 
2) 古川福実, 他 (日本皮膚科学血管炎・血管障害診療ガイドライン改訂版作成委員会). 血管炎・血管障害診療ガイドライン 2016年改訂版. 日皮会誌. 2017 ; 127 : 299.
 

4章 血小板数低下を伴う血栓性疾患

P.299 掲載の参考文献
1) 朝倉英策. 播種性血管内凝固症候群 (DIC). In : 朝倉英策, 編. しみじみわかる血栓止血 vol.1 DIC・血液凝固検査編. 東京 : 中外医学社 ; 2014. p.47
 
2) Asakura H. Classifying types of disseminated intravascular coagulation : clinical and animal models. J Intensive Care. 2014 ; 2 : 20.
PubMed
3) Matthay MA. Severe sepsis a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001 ; 344 : 759.
PubMed
4) Menell JS, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999 ; 340 : 994.
PubMed
5) Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31.
PubMed
P.307 掲載の参考文献
1) 青木延雄, 他. DIC診断基準の「診断のための補助的検査成績, 所見」の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班, 昭和62年度研究報告書. 1988. p.37.
 
2) Taylor FB Jr, et al. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) : towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 : 1327.
 
3) 丸藤哲, 他. 急性期DIC診断基準多施設共同前向き試験結果報告. 日救急医会誌. 2005 ; 16 : 188.
 
4) 日本血栓止血学会 DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準暫定案. 血栓止血会誌. 2014 ; 25 : 629.
 
5) Asakura H, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016 ; 14 : 42.
PubMed
6) 日本血栓止血学会 DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血会誌. 2017 ; 28 : 369.
 
7) Wada H, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017 ; 15 : 17.
PubMed
8) 日本血栓止血学会学術標準化委員会DIC部会. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 血栓止血誌. 2009 ; 20 : 77.
 
9) Asakura H. Classifying types of disseminated intravascular coagulation : clinical and animal models. J Intensive Care. 2014 ; 2 : 20.
PubMed
P.315 掲載の参考文献
1) 中川雅夫. 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会, 平成10年研究業績報告書. 1999. p.57.
 
2) Sack GH Jr, et al. Trousseau's syndrome and other manifestations of chronic disseminated coagulopaty in patients with neoplasms : Clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977 ; 56 : 1.
 
3) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 : 1723.
PubMed
4) Gouin-Thibault I, et al. Labolatory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999 ; 25 : 167.
 
5) Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol. 2009 ; 22 : 129.
PubMed
6) Labelle M, et al. The initial hours of metastasis : the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012 : 2 ; 1091.
PubMed
7) Seki Y, et al. Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy. Int J Hematol. 2016 : 104 ; 506.
 
8) Seki Y, et al. In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005 ; 115 : 219.
PubMed
9) 朝倉英策, 他. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血誌. 2017 ; 28 : 369.
 
10) Klerk CP, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005 ; 23 : 2130.
PubMed
11) Tamura K, et al. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors : results of a one-arm prospective trial. Int J Clin Oncol. 2015 ; 20 : 821.
PubMed
P.321 掲載の参考文献
1) 中川雅夫. 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会, 平成10年度研究業績報告書. 1999. p.57.
 
2) Kawasugi K, et al. (Japanese Society of Thrombosis Hemostasis/DIC subcommittee). Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying disease. Thromb Res. 2011 ; 128 : 186.
PubMed
3) Yamada M, et al. Disseminated intravascular coagulation in acute leukemia : clinical and laboratory features at presentation. Eur J Haematol. 2006 ; 77 : 282.
 
4) Uchiumi H, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 2007 ; 86 : 137.
PubMed
5) Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of phase III randomized double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31.
PubMed
6) Dellinger RP, et al. Surviving Sepsis Campain : International Guidelines for Management of Severe Sepsis and Septic Shock : 2012. Critical Care Medicine. 2012 ; 41 : 580.
 
P.326 掲載の参考文献
1) Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014 ; 100 : 27.
PubMed
2) Yan J, et al. PML/RARα fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Proc Natl Acad Sci U S A. 2010 ; 107 : 3716.
 
3) O'Connell PA, et al. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood. 2011 ; 117 : 4095.
 
4) Lehmann S, et al. Early death rates remain high in high-risk APL : update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017 ; 31 : 1457.
PubMed
5) Jacomo RH, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007 ; 92 : 1431.
PubMed
6) Sanz MA, et al. Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 ; 113 : 1875.
 
7) Matsushita T, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation : a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014 ; 133 : 772.
PubMed
8) Ikezoe T, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res. 2012 ; 36 : 1398.
PubMed
9) Ikezoe T, et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp Hematol. 2012 ; 40 : 457.
PubMed
10) Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31.
PubMed
11) Breccia M, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007 ; 21 : 79.
PubMed
12) Kojima S, et al. In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome. Leuk Res. 2017 ; 63 : 1.
PubMed
P.332 掲載の参考文献
1) Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004 ; 344 : 13.
PubMed
2) Taylor Jr FB, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001 ; 86 : 1327.
 
3) Takemitsu T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost. 2011 ; 105 : 40.
PubMed
4) Asakura H, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016 ; 14 : 42. Review.
PubMed
5) Wada H, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017 ; 15 : 17.
PubMed
6) Wada H, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee : expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010 ; 125 : 6.
PubMed
7) Wada H, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013 11 : 761.
 
P.338 掲載の参考文献
1) Bone RC, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 ; 101 : 1644.
PubMed
2) Singer M, et al. THe third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016 ; 315 : 801.
PubMed
3) Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007 ; 449 : 819.
PubMed
4) Chen GY, et al. Sterile inflammation : sensing and reacting to damage. Nature Rev Immunol. 2010 ; 10 : 826.
PubMed
5) Cole JN, et al. Molecular insight into invasive group A streptococcal disease. Nature Reviews Microbiol. 2011 ; 9 : 724.
 
6) Niessen F, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature. 2008 ; 452 : 654.
PubMed
7) Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014 ; 2 : 67.
PubMed
8) Furlan-Freguia C, et al. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest. 2011 ; 121 : 2932.
PubMed
9) Engelmann B, et al. Thrombosis as an intravascular effector of innate immunity. Nature Rev Immunol. 2013 ; 13 : 34.
 
10) Matzinger P. The danger model : a renewed sense of self. Science. 2002 ; 296 : 301.
 
11) Bianchi ME. DAMPs, PAMPs and alarmins : all we need to know about danger. J Leukoc Biol. 2007 ; 81 : 1.
 
P.344 掲載の参考文献
1) Hayakawa M. Pathophysiology of trauma-induced coagulopathy : disseminated intravascular coagulation with the fibrinolytic phenotype. J Intensive care. 2017 ; 5 : 14.
PubMed
2) 早川峰司. 【外傷性凝固障害の病態と対応】 外傷性DICの病態 線溶亢進から線溶抑制へ. Thromb Med. 2017 ; 7 : 250.
 
3) Chandler WL. Procoagulant activity in trauma patients. Am J Clin Pathol. 2010 ; 134 : 90.
PubMed
4) Dunbar NM, et al. Thrombin generation in trauma patients. Transfusion. 2009 ; 49 : 2652.
PubMed
5) Hayakawa M, et al. Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma : a retrospective observational study. Semin Thromb Hemost. 2015 ; 41 : 35.
PubMed
P.349 掲載の参考文献
1) Kwaan HC, et al. A study of pancreatic enzymes as a factor in the pathogenesis of disseminated intravascular coagulation during acute pancreatitis. Surgery. 1971 ; 69 : 663.
PubMed
2) 急性膵炎診療ガイドライン2015改訂出版委員会, 編. 急性膵炎診療ガイドライン 2015. 東京 : 金原出版 ; 2015.
 
3) Maeda K, et al. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas. 2006 ; 32 : 87.
PubMed
4) Tsokos M, et al. Acute pancreatitis presenting as sudden, unexpected death : an autopsy-based study of 27 cases. Am J Forensic Med Pathol. 2007 ; 28 : 267.
PubMed
5) Murata A, et al. The recent time trend of outcomes of disseminated intravascular coagulation in Japan : an observational study based on a national administrative database. J Thromb Thrombolysis. 2014 ; 38 : 364.
PubMed
6) 丸藤哲, 他. 急性期DIC診断基準 多施設共同前向き試験結果報告. 日救急医会誌. 2005 ; 16 : 188.
 
7) Hirota M, et al. Acute pancreatitis bundles : 10 clinical regulations for the early management of patients with severe acute pancreatitis in Japan. J Hepatobiliary Pancreat Sci. 2014 ; 21 : 829.
PubMed
8) Eguchi T, et al. Efficacy of recombinant human soluble thrombomodulin in preventing walled-off necrosis in severe acute pancreatitis patients. Pancreatology. 2015 ; 15 : 485.
PubMed
P.354 掲載の参考文献
1) Fine NL, et al. Multiple coagulation defects in association with dissecting aneurysm. Arch Intern Med. 1967 ; 119 : 522.
PubMed
2) Fisher DF Jr, et al. Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg. 1983 ; 118 : 1252.
PubMed
3) Levi M, et al. Disseminated intravascular coagulation. N Engl J Med. 1999 ; 341 : 586.
PubMed
4) Shimazaki T, et al. Blood coagulation and fibrinolytic response after endovascular stent grafting of thoracic aorta. J Vasc Surg. 2003 ; 37 : 1213.
PubMed
5) Ontachi Y, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J. 2005 ; 69 : 1150.
PubMed
6) Yasumoto A, et al. Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations. Blood Coagul Fibrinolysis. 2017 ; 28 : 670.
PubMed
7) Hayashi T, et al. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm : a case report. Ann Intern Med. 2014 ; 161 : 158.
 
8) Kadohira Y, et al. Aortic aneurysm-associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med. 2017 ; 56 : 2913.
PubMed
9) Suzuki T, et al. Diagnosis of acute aortic dissection by D-dimer. Circulation. 2009 ; 119 : 2702.
PubMed
P.359 掲載の参考文献
1) Taylor FB Jr, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 : 1327.
 
2) DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血会誌. 2017 ; 28 : 369.
 
3) Gando S, et al ; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med. 2006 ; 34 : 625.
 
4) 内場光浩. DIC ; 凝固系制御と線溶系制御の破綻. 日検査血液会誌. 2018 ; 19 : 1.
 
5) 福武勝幸. Dダイマーの現状と標準化に向けた課題. 生物試料分析. 2009 ; 32 : 380.
Medical*Online
6) 内場光浩. 実臨床における凝固線溶検査のピットフォール. 血栓止血会誌. 2018 ; 29 : 28.
 
7) Uchiba M, et al. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid. 2009 ; 16 : 89.
PubMed
P.367 掲載の参考文献
1) Asakura H. Classifying types of disseminated intravascular coagulation : Clinical and animal models. J Intensive Care. 2014 ; 2 : 20.
PubMed
2) 中川雅夫. 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会. 平成10年度研究業績報告書. 1999. p.57.
 
3) Kawasugi K, et al. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying disease. Thromb Res. 2011 ; 128 : 186.
PubMed
4) 伊藤隆史. 炎症に伴う血液凝固異常. In : 一瀬白帝, 他編. 新・血栓止血血管学 凝固と炎症. 京都 : 金芳堂 ; 2015. p.149.
 
5) 持田智. 【徹底ガイドDICのすべて 2014-15】急性肝不全. 救急・集中治療. 2014 ; 26 : 839.
 
6) 内山俊正. 厚生省DIC診断基準の背景-その成立から現在まで-. 血栓止血誌. 2010 ; 21 : 562.
 
7) 日本血栓止血学会DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血誌. 2017 : 28 : 368.
 
8) 内山俊正. DIC診断と肝障害. 機器・試薬. 2017 ; 40 : 320.
Medical*Online
9) 日本血栓止血学会学術標準化委員会DIC部会. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 血栓止血誌. 2009 ; 20 : 77.
 
10) 日本血栓止血学会学術標準化委員会DIC部会ガイドライン作成委員会. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサスの追補. 血栓止血誌. 2014 : 25 : 123.
 
P.372 掲載の参考文献
1) 日本救急医学会熱中症に関する委員会. 熱中症診療ガイドライン 2015. http://www.jaam.jp/html/info/2015/pdf/info-20150413.pdf.
 
2) Bouchama A, et al. Heat stroke. N Engl J Med. 2002 ; 346 : 1978.
PubMed
3) Huisse MG, et al. Leukocyte activation : the link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris. Crit Care Med. 2008 ; 36 : 2288.
PubMed
4) Bouchama A, et al. Activation of coagulation and fibrinolysis in heatstroke. Thromb Haemost. 1996 ; 76 : 909.
PubMed
5) Hifumi T, et al. Prognostic significance of disseminated intravascular coagulation in patients with heat stroke in a nationwide registry. J Crit Care. 2018 ; 44 : 306.
 
6) 日本救急医学会. 熱. 本邦における熱中症の現状-Heatstroke STUDY 2010最終報告-. 日救急医会誌. 2012 ; 23 : 211.
 
7) 三宅康, 他. 熱中症の実態調査-Heatstroke STUDY 2006最終報告-. 日救急医会誌. 2008 ; 19 : 309.
 
P.379 掲載の参考文献
1) Gando S, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med. 2006 ; 34 : 625.
PubMed
2) 朝倉英策, 他. 日本血栓止血学会 DIC診断基準 2017年版. 血栓止血誌. 2017 ; 28 : 369.
 
3) Okamoto K, et al. Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res. 2010 ; 126 : 74.
PubMed
4) Okamoto K, et al. Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016 ; 4 : 23.
PubMed
5) 岡本好司, 他. HMGB1の基礎と臨床. 血栓止血会誌. 2010 ; 21 : 619.
 
6) Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999 ; 285 : 248.
PubMed
7) 岡本好司, 他. 腹部救急領域における敗血症性DICの病態・診断について 日腹部救急医会誌. 2017 ; 37 : 711.
 
8) Nagato M, et al. Recombinant human soluble thrombomodulin (ART-123) decreases the plasma HMGB1 levels, while improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med. 2009 ; 37 : 2181.
PubMed
P.385 掲載の参考文献
1) Andrew M. The hemostatic system in the infant. In : Nathan DG, Osaki FA, ed. Hematology of infancy and children. 4 th ed. Philadelphia : Saunders Co ; 1992. p.115.
 
2) 三上貞昭. 新生児の凝固機構. 産婦血液. 1987 ; 11 : 133.
 
3) 青木延雄, 長谷川淳. DIC診断基準の『診断のための補助的検査成績, 所見』の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集. 1988. p.37.
 
4) Gando S, et al ; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med. 2006 ; 34 : 625.
 
5) Taylor FB Jr, et al ; Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 : 1327.
 
6) 朝倉英策, 他 ; 日本血栓止血学会DIC診断基準作成委員会. DIC診断基準暫定案. 血栓止血誌. 2014 ; 25 : 629.
 
7) 朝倉英策, 他 ; 日本血栓止血学会DIC診断基準作成委員会. DIC診断基準 2017年版. 血栓止血誌. 2017 ; 28 : 369.
 
8) 白幡聡. 新生児出血性疾患. 周産期医. 1996 ; 22 : 1443.
 
9) 河井昌彦. 早期新生児期のDIC診断基準の考案 プロトロンビン時間を重視した診断基準作成の試み. 周産期新生児誌. 2007 ; 43 : 10.
 
10) 川口千晴, 他. 新生児DICの診断・治療に関する全国アンケート調査 新生児DIC全国調査. 日産婦新生児血会誌. 2016 ; 26 : 43.
Medical*Online
11) 白幡聡, 他 ; 日本産婦人科・新生児血液学会 新生児DIC診断・治療指針作成ワーキンググループ. 新生児DIC診断・治療指針 2016年版. 日産婦新生児血会誌. 2016 ; 25 : 3.
 
P.393 掲載の参考文献
1) 小林隆夫. 産科DIC. In : 日本産婦人科・新生児血液学会, 編. 産婦人科・新生児領域の血液疾患診療の手引き. 東京 : メディカルビュー社 ; 2017. p.97.
 
2) 小林隆夫. 産科DICにおけるアンチトロンビン III (AT) 製剤の使用方法. Coagul Inflamm. 2016 ; 2 : 11.
 
3) 小林隆夫. 産科DICの診断・治療. 救急医学. 2015 ; 39 : 1595.
 
4) 小林隆夫. 産科DICの特徴とDICスコア. DIC-診断・治療の最前線. 医学のあゆみ. 2011 ; 238 : 77.
 
5) 真木正博, 他. 産科DICスコア. 産婦治療. 1985 ; 50 : 119.
 
6) 日本産科婦人科学会, 他編. 産科危機的出血への対応指針 2017. http://www.jsog.or.jp/activity/pdf/shusanki_shishin2017.pdf
 
7) WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN) : an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 ; 389 : 2105.
PubMed
8) Kobayashi T, et al. Recombinant activated factor VII (rFVIIa/NovoSeven(R)) in the management of severe postpartum haemorrhage : initial report of a multicentre case series in Japan. Int J Hematol. 2012 ; 95 : 57.
 
9) Murakami M, et al. Experience with recombinant activated factor VII for severe postpartum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015 ; 41 : 1161.
 
10) Makino S, et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan : Investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015 ; 41 : 1155.
 
P.399 掲載の参考文献
1) Scully M, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 ; 15 : 312.
PubMed
2) 松本雅則, 他. 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液. 2017 ; 58 : 271.
 
3) Rock GA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991 ; 325 : 393.
 
4) Scully M, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 ; 158 : 323.
PubMed
5) Scully M, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011 ; 118 : 1746.
 
6) Amorosi EL, et al. Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literature. Medicine. 1966 ; 45 : 139.
 
P.404 掲載の参考文献
1) Gasser C, et al. Hemolytic-uremic syndrome : bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955 ; 85 : 905.
PubMed
2) 松本雅則, 他. 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液. 2017 ; 58 : 271.
 
3) 香美祥二, 他. 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日腎会誌. 2016 ; 58 : 62.
 
4) Noris M, et al. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009 ; 361 : 1676.
PubMed
5) Fujisawa M, et al. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol. 2018.
PubMed
6) Legendre CM, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 ; 368 : 2169.
PubMed
P.409 掲載の参考文献
1) Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count ; a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 1982 ; 142 : 159.
PubMed
2) Kobayashi T, et al. Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome : proposal of angiospastic syndrome of pregnancy. Semin Thrombo Hemost. 2001 ; 27 : 131.
 
3) 小林隆夫. HELLP症候群. 医薬の門. 2003 ; 43 : 77.
 
4) 小林隆夫. Q33. HELLP症候群 やさしく学べる血小板・血栓止血の管理. 救急・集中治療. 2008 ; 20 : 719.
 
5) Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) : much ado about nothing? Am J Obstet Gynecol. 1990 ; 162 : 311.
PubMed
6) 日本妊娠中毒症学会学術委員会. HELLP症候群に関する定義・用語についての提案. 日妊娠中毒症会誌. 2001 ; 9 : 30.
 
7) CQ313. 妊産褥婦にHELLP症候群・臨床的急性妊娠脂肪肝を疑ったら? In : 日本産科婦人科学会/日本産婦人科医会, 編・監. 産婦人科診療ガイドライン-産科編 2017. 東京 : 日本産科婦人科学会 ; 2017. p.230.
 
8) Kobayashi T, et al. Antocholinergics induces eclamptic seizures. Semin Thromb Hemost. 2002 ; 28 : 511.
PubMed
9) 小林隆夫. 周産期診療べからず集. 妊婦の上腹部症状にブチルスコポラミン (ブスコパン(R) は使うべからず. 周産期医学. 2015 ; 45 増刊号 : 154.
 
10) 小林隆夫. HELLP症候群, 子癇, 非典型HUSの関係. In : 宮川義隆, 他編. 血栓性微小血管症 (TMA) 診断・治療マニュアル. 大阪 : 医薬ジャーナル社 ; 2016. p92.
 
P.415 掲載の参考文献
1) 安本篤史. ヘパリン起因性血小板減少症 (HIT) 診断の最新検査. 医学のあゆみ. 2017 ; 263 : 1163.
Medical*Online
2) 安本篤史. ヘパリン起因性血小板減少症 (HIT) の最新の診断・検査. 臨床検査. 2017 ; 61 : 140.
 
3) 宮田茂樹, 他. 免疫学的特異性に基づいたヘパリン起因性血小板減少症 (HIT) の適切な診断と治療. 臨床血液. 2016 ; 57 (3) : 322-32.
 
4) Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015 ; 373 : 252.
PubMed
5) Maeda T. Impact of heparin-induced thrombocytopenia on acute coronary artery thrombosis in patients undergoing PCI. Thromb Haemost. 2014 ; 112 : 624.
PubMed
6) Warkentin TE. Direct oral anticoagulants for treatment of HIT : update of Hamilton experience and literature review. Blood. 2017 ; 130 : 1104.
PubMed
P.422 掲載の参考文献
1) Carreras E, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011 ; 17 : 1713.
PubMed
2) Mohty M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016 ; 51 : 906.
PubMed
3) Carreras E, et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant. 1993 ; 11 : 21.
PubMed
4) Richardson PG, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 ; 127 : 1656.
PubMed
5) Cho B, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010 ; 90 : 91.
 
6) Ikezoe T, et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010 ; 45 : 783.
PubMed
7) Sakai M, et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010 ; 45 : 803.
PubMed
8) Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost. 2013 ; 109 : 416.
PubMed
9) Carreras E, et al. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011 ; 46 : 1495.
PubMed

5章 血栓性疾患

P.431 掲載の参考文献
1) Ohga S, et al. Japan Childhood Thrombophilia Study Group. Protein C deficiency as the major cause of thrombophilias in childhood. Pediatr Int. 2013 ; 55 : 267.
 
2) Lijfering WM, et al. Selective testing for thrombophilia in patients with first venous thrombosis. Results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009 ; 113 : 5314.
PubMed
3) Mahmoodi BK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010 ; 8 : 1193.
PubMed
4) Ichiyama M, et al. Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism. Pediatr Res. 2016, 79 : 81.
PubMed
5) Miyata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009 ; 124 : 14.
PubMed
6) Bates SM, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy : antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141 (2 Suppl) : e691S.
 
P.437 掲載の参考文献
1) Miyawaki Y, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012 ; 366 : 2390.
PubMed
2) Matsushita T, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. (The authors reply) N Engl J Med. 2012 ; 367 : 1069.
 
3) Bertina RM, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 ; 369 : 64.
PubMed
4) Miyata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009 ; 124 : 14.
PubMed
5) 酒井道生, 他. 乳児発症例を含む血栓症多発の1家系. J UOEH (産業医科大学雑誌). 2001 ; 23 : 297.
 
6) ten Kate M, et al. A genome wide linkage scan for thrombosis susceptibility genes identifies a novel prothrombin mutation. XXII Congress of ISTH, Boston. 2009 ; OC-WE-098 (Abstract)
 
7) Li W, et al. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol. 2004 ; 11 : 857.
PubMed
8) Murata M, et al. Development of a new laboratory test to evaluate antithrombin resistance in plasma. Thromb Res. 2014 ; 133 : 293.
PubMed
9) Kishimoto M, et al. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol. 2016 ; 95 : 541.
PubMed
10) Tamura S, et al. Optimisation of antithrombin resistance assay as a practical clinical laboratory test : development of prothrombin activator using factors Xa/Va and automation of assay. Int J Lab Hematol. 2018. in press.
 
11) Djordjevic V, et al. A novel prothrombin mutation in two families with prominent thrombophilia-the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost. 2013 ; 11 : 1936.
 
12) Sivasundar S, et al. Molecular defect of 'Prothrombin Amrita' : substitution of arginine by glutamine (Arg553 to Gln) near the Na (+) binding loop of prothrombin. Blood Cells Mol Dis. 2013 ; 50 : 182.
PubMed
13) Yoshida R, et al. Familial pulmonary thromboembolism with a prothrombin mutation and antithrombin resistance. J Cardiol Cases. 2018. in press.
 
14) Wu X, et al. Screening and functional exploration of prothrombin Arg596 related mutations in Chinese venous thromboembolism patients. J Clin Pathol. 2018. in press.
 
15) Bulato C, et al. New prothrombin mutation (Arg596Trp, prothrombin padua 2) associated with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2016 ; 36 : 1022.
PubMed
P.443 掲載の参考文献
1) 安達知子. AT欠乏症, PC欠乏症, PS欠乏症と妊娠・分娩. In : 鈴木重統, 他編. 止血・血栓ハンドブック. 東京 : 西村書店 ; 2015. p.350.
 
2) Hirsh J, et al. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals from the council on thrombosis, American Heart Association. Circulation. 1996 ; 93 : 2212.
PubMed
3) 安達知子. 妊娠と血栓症. 臨床検査. 2009 ; 53 : 1139.
 
4) American College of Obstetricians and Gynecologists Women's Health Care Physicians. ACOG Practice Bulletin No. 138 : Inherited thrombophilias in pregnancy. Obstet Gynecol. 2013 ; 122 : 706.
PubMed
5) 安達知子. アンチトロンビン欠乏症と妊娠. 産科と婦人科. 2013 ; 80 : 72.
Medical*Online
6) 水上尚典, 他. 妊娠性アンチトロンビン欠乏症. 日産婦新生児血会誌. 2010 ; 19 : 7.
Medical*Online
7) 安達知子. 妊娠・分娩と凝固抑制因子の異常 妊娠・分娩と血液異常. 血液フロンティア. 2007 ; 17 : 899.
 
8) 宮田敏行, 他. 日本人の血栓性素因, 特にプロテインS欠損症を中心に. review. 日産婦新生児血液会誌. 2011 ; 20 : 75.
 
9) 鈴木敦夫. エストラジオールによるPS遺伝子の発現抑制機構. 血栓止血会誌. 2012 ; 23 : 407.
 
10) 安達知子. 周産期に留意すべき凝固異常～先天性血栓性素因「アンチトロンビン欠乏症」合併妊娠. Thrombosis Medicine. 2018 ; 8 : 63.
Medical*Online
11) 安達知子, 他. ヘパリン療法の基礎. In : 鈴木重統一, 他編. 止血・血栓ハンドブック. 東京 : 西村書店 ; 2015. p.200.
 
12) Bates SM, et al. Thrombophilia, antithrombotic therapy, and pregnancy : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141 (2 Suppl) : e691S.
 
13) Adachi T. Protein S and congenital protein S deficiency : the most frequent congenitalthrombophilia in Japanese. Current Drug Targets. 2005 ; 6 : 585.
PubMed
P.450 掲載の参考文献
1) Cervera R, et al. The Euro-Phospholipid project : epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009 ; 18 : 889.
PubMed
2) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295.
 
3) Pengo V, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 ; 93 : 1147.
PubMed
4) Lim W, et al. Management of antiphospholipid antibody syndrome : a systematic review. JAMA. 2006 ; 295 : 1050.
PubMed
5) Elkan D, et al. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011 ; 20 : 219.
 
P.455 掲載の参考文献
1) Harris EN. Syndrome of the black swan. Br J Rheumatol. 1987 ; 26 : 324.
 
2) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295.
 
3) Sciascia S, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016 ; 214 : 273.
 
4) Ruffatti A, et al. Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome : a multicentre study. Thromb Haemost. 2018 ; 118 : 639.
PubMed
5) Costantine MM. Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. J Clin Invest. 2016 ; 126 : 2792.
PubMed
6) Sekiya A, et al. Thrombosis prediction based on reference ranges of coagulation-related markers in different stages of pregnancy. Clin Appl Thromb Hemost. 2017 ; 23 : 844.
PubMed
P.462 掲載の参考文献
1) 日本循環器学会. 循環器病ガイドラインシリーズ 2017年版 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_ito_h.pdf
 
2) Kearon C, et al : Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest. 2016 ; 149 : 315.
 
3) Konstantinides SV, et al ; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014 ; 35 : 3033.
 
4) Weitz JI, et al ; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 ; 376 : 1211.
 
5) Agnelli G, et al ; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 ; 368 : 699.
PubMed
P.466 掲載の参考文献
1) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. 東京 : メディカルフロントインターナショナルリミテッド ; 2004.
 
2) 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン (2017年改訂版), http://www.j-circ.or.jp/guideline/pdf/JCS2017_itoh_h.pdf
 
3) 医療事故調査・支援センター, 日本医療安全調査機構. 急性肺血栓塞栓症に係る死亡事例の分析 (平成29年8月). https://www.medsafe.or.jp/uploads/uploads/files/teigen-02.pdf
 
4) CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1) : a multicentre, randomised controlled trial. Lancet. 2009 ; 373 : 1958.
PubMed
5) Guyatt GH, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141 : 7S.
PubMed
6) CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke : a randomized trial. Ann Intern Med. 2010 ; 153 : 553.
PubMed
P.473 掲載の参考文献
1) TASC II Working Group/日本脈管学会, 編. 下肢閉塞性動脈硬化症の診断・治療指針 II : 日本脈管学会. 東京 : メディカルトリビューン社 ; 2007.
 
2) Bhatt DL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 ; 295 : 180.
 
3) Yamazaki T, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007 ; 71 : 995.
PubMed
4) Steg PG, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297 : 1197.
PubMed
5) Alberts MJ, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health registry. Eur Heart J. 2009 ; 30 : 2318.
PubMed
6) 日本循環器学会, 他. 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版).
 
7) Rooke TW, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg. 2011 ; 54 (5) : e32.
 
8) Ishimoto Y, et al. Prevalence of symptomatic lumbar spinal stenosis and its association with physical performance in a population-based cohort in Japan : the Wakayama Spine Study. Osteoarthritis Cartilage. 2012 ; 20 : 1103.
 
P.478 掲載の参考文献
1) Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001 ; 104 : 365.
PubMed
2) ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
3) Sato Y, et al. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart. 2005 ; 91 : 526.
PubMed
4) Fremes SE, et al. Optimal antithrombotic therapy following aortocoronary bypass : a meta-analysis. Eur J Cardiothorac Surg. 1993 ; 7 : 169.
PubMed
5) Kruger D, et al. Exercise-induced myocardial ischemia in isolated coronary artery ectasias and aneurysms ("dilated coronopathy"). J Am Coll Cardiol. 1999 ; 34 : 1461.
PubMed
6) Saito R, et al. Nutri-pharmacogenomics of warfarin anticoagulation therapy : VKORC1 genotype-dependent influence of dietary vitamin K intake. J Thromb Thrombolysis. 2014 ; 38 : 105.
PubMed
7) 後藤信哉. 循環器疾患と血栓症 : thrombo-cardiologyの概念. 循環器内科. 2016 ; 79 : 1.
 
8) IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina : the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002 ; 359 : 1269. Erratum in : Lancet 2002 ; 360 : 806.
 
9) Lee CC, et al. Use of nicorandil is associated with increased risk for gastrointestinal ulceration and perforation-a nationally representative population-based study. Sci Rep. 2015 ; 5 : 11495.
PubMed
10) Heyde EC. Gasterointesinal bleeding in aortic stenosis. N Engl J Med. 1958 ; 259 : 196.
 
P.484 掲載の参考文献
1) Tamura Y, et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res. 1986 ; 25 : 461.
PubMed
2) Yokoyama M, et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet. 2007 ; 369 : 1090.
PubMed
3) 大荷満生. 高トリグリセリド血症と凝固線溶系因子. In : 秦葭哉, 編. 新高トリグリセライド血症ハンドブック. 東京 : 医薬ジャーナル社. p.138.
 
4) Kooistra T, et al. Plasminogen activator inhibitor 1 : biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989 ; 62 : 723.
PubMed
5) Stiko-Rahm A, et al. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990 ; 10 : 1067.
PubMed
6) Shimomura I, et al. Enhanced expression of PAI-1 in visceral fat : possible contributor to vascular disease in obesity. Nat Med. 1996 ; 2 : 800.
PubMed
7) Kohno M, et al. Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metab ClinExp. 1997 ; 46 : 287.
 
8) Iso H, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001 ; 153 : 490.
PubMed
9) Todo Y, et al. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype. Clin Chim Acta. 2004 ; 348 : 35.
PubMed
10) Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420 : 868.
PubMed
P.491 掲載の参考文献
1) 厚生労働科学研究費補助金 難治性疾患克服研究事業. 特発性造血障害に関する調査研究班 (主任研究者 小峰光博) /PNHの診断基準と診療の参照ガイド作成のためのワーキンググループ. 発作性夜間ヘモグロビン尿症診療の参照ガイド. 2005.
 
2) Hall C, et al. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003 ; 102 : 3587.
PubMed
3) Hillmen P, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 ; 110 : 4123.
PubMed
4) Van Bijnen ST, et al. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012 ; 10 : 1.
PubMed
5) Weitz IC, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 ; 130 : 361.
PubMed
P.497 掲載の参考文献
1) Parker C, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 ; 106 : 3699.
PubMed
2) McKeage K. Eculizumab : a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011 ; 71 : 2327.
PubMed
3) Nishimura J, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004 ; 83 : 193.
PubMed
4) Schrezenmeier H, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014 ; 99 : 922.
PubMed
5) Lee JW, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013 ; 97 : 749.
PubMed
6) Rother RP, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin : a novel mechanism of human disease. JAMA. 2005 ; 293 : 1653.
PubMed
7) Hill A, et al. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013 ; 121 : 4985.
PubMed
8) 西村純一. Eculizumab時代の発作性夜間ヘモグロビン尿症と血栓症. 臨血 2018 ; 59 : 1042.
 
9) Rother RP, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 ; 25 : 1256.
PubMed
10) Hillmen P, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 ; 110 : 4123.
PubMed
11) PNH妊婦の参照ガイド (付記). http://zoketsushogaihan.com/file/guideline_H26/PNH-ninpu.pdf
 
P.504 掲載の参考文献
1) Marchioli R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 ; 23 : 2224.
 
2) Chim CS, et al. Long-term outcome of 231 patients with essential thrombocythemia : prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005 ; 165 : 2651.
PubMed
3) Smalberg JH, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis : a meta-analysis. Blood. 2012 ; 120 : 4921.
PubMed
4) Cortelazzo S, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 ; 332 : 1132.
 
5) Barbui T, et al. Myeloproliferative neoplasms and thrombosis. Blood. 2013 ; 122 : 2176.
PubMed
6) Federici AB, et al. Acquired von Willebrand syndrome : data from an international registry. Thromb Haemost. 2000 ; 84 : 345.
 
7) Rumi E, et al. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017 ; 129 : 680.
PubMed
8) Barbui T, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 ; 120 : 5128.
PubMed
9) Tefferi A, et al. Polycythemia vera and essential thrombocythemia : 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017 ; 92 : 94.
PubMed
10) Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 ; 368 : 22.
PubMed
11) Foucar CE, et al. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis. JAMA. 2017 ; 317 : 2228.
PubMed
P.509 掲載の参考文献
1) Fotiou D, et al. A review of the venous thrombotic issues associated with multiple myeloma. Expert Rev Hematol. 2016 ; 9 : 695.
PubMed
2) Hideshima T, et al. Advances in biology of multiple myeloma : clinical applications. Blood. 2004 ; 104 : 607.
PubMed
3) Zangari M, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002 ; 13 : 187.
PubMed
4) Undas A, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients : association with thromboembolic complications. Blood Coagul Fibrinolysis. 2015 ; 26 : 621.
PubMed
5) Barlogie B, et al. Treatment of multiple myeloma. Blood. 2004 ; 103 : 20.
 
6) Rupa-Matysek J, et al. Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. Thromb Res. 2014 ; 134 : 404.
PubMed
7) Becattini C, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 ; 366 : 1959.
PubMed
P.515 掲載の参考文献
1) Wakker AJ, et al. Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer. 2013 ; 49 : 1404.
 
2) Timp JF, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 ; 122 : 1712.
PubMed
3) Carrier M, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 ; 373 : 697.
PubMed
4) Carrier M, et al. Systematic review : the Trousseau syndrome revisited : should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008 ; 149 : 323.
PubMed
5) Van Es N, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism : evidence from phase 3 trials. Blood. 2014 ; 124 : 1968.
PubMed
6) Lee AYY, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer : a randomized clinical trial. JAMA. 2015 ; 314 : 677.
 
7) Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 ; 378 : 615.
PubMed
8) Facon T,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trial. Lancet. 2007 ; 370 : 1209.
PubMed
9) Palumbo A, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 ; 22 : 414.
PubMed
10) Gieseler F. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost. 2008 ; 99 : 1001.
PubMed
11) Caruso V, et al. Thrombotic complications in childhood acute lymphoblastic leukemia : a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006 ; 108 : 2216.
PubMed
12) Abbott LS, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009 ; 114 : 5146.
PubMed
13) Lauw MN, et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia : effect of fresh frozen plasma supplementation. Thromb Haemost. 2013 ; 109 : 633.
PubMed
14) Palumbo A, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide : a phase III, open-label, randomized trial. J Clin Oncol. 2011 ; 29 : 986.
 
P.518 掲載の参考文献
1) Michaud M, et al. Cryofibrinogenemia. J Clin Rheumatol. 2013 ; 19 : 142.
 
2) 岡崎怜子, 他. コレステロール結晶塞栓症. 日医大医会誌. 2006 ; 2 : 115.
Medical*Online
3) 藤本学, 他, (日本皮膚科創傷・熱傷ガイドライン作成委員会). 膠原病・血管炎にともなう皮膚潰瘍診療ガイドライン. 日皮会誌. 2017 ; 127 : 2033.
 
P.523 掲載の参考文献
1) de Bastos M, et al. Combined oral contraceptives : venous thrombosis. Cochrane Database Syst Rev. 2014 ; 3 : CD010813.
PubMed
2) Sugiura K, et al. Thromboembolism as the adverse event of combined oral contraceptives in Japan. Thromb Res. 2015 ; 136 : 1110.
PubMed
3) Martinez F, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2012 ; 17 : 7.
PubMed
4) van Hylckama Vlieg A, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type : results of the MEGA case-control study. BMJ. 2009 ; 339 : b2921.
 
5) Wiegratz I, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004 ; 70 : 97.
PubMed
6) Garcia de Frutos P, et al. Molecular basis of protein S deficiency. Thromb Haemost. 2007 ; 98 : 543.
PubMed
7) Miyata T, et al. Thrombophilia in East Asian countries : are there any genetic differences in these countries? Thromb J. 2016 ; 14 : 25.
PubMed
8) van Sluis GL, et al. Family history and inherited thrombophilia. J Thromb Haemost. 2006 ; 4 : 2182.
PubMed
9) Maruyama K, et al. ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism. PLoS One 2015 ; 10 : e0133196.
PubMed

6章 抗血栓療法

P.531 掲載の参考文献
1) Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 33 : 1849.
 
2) Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 : 71.
PubMed
3) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). 日本循環器学会ホームページ. http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf
 
4) Nagatsuka I, et al. Cardiovascular events occur independently of high-on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. Thromb Haemost. 2016 ; 116 : 356.
 
5) CAPRIE steering committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 ; 348 : 1329.
 
6) Shinohara Y, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 ; 9 : 959.
PubMed
7) Toyoda K, et al. Dual antithrombotic therapy increase severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke. 2008 ; 39 : 1740.
PubMed
8) Ikeda Y, et al. Low dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors : a randomized clinical trial. JAMA. 2014 ; 312 : 2510.
Medical*Online
P.536 掲載の参考文献
1) 前川正. ワーファリン. In : 前川正, 他編. 東京 : メディカル・ジャーナル社 ; 1990. p.1.
 
2) エーザイ : ワルファリンの作用機序. In : 青崎正彦, 他監. Warfarin適正使用情報. 第3版. 東京 : エーザイ ; 2006. p.17.
 
3) エーザイ : 体内薬物動態. In : 青崎正彦, 他監. Warfarin適正使用情報. 第3版. 東京 : エーザイ ; 2006. p.92.
 
P.541 掲載の参考文献
1) Hylek EM, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000 ; 160 : 1612.
PubMed
2) Sjoblom L, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy : a Swedish multicenter study. Stroke. 2001 ; 32 : 2567.
PubMed
3) Yasaka M, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003 ; 89 : 278.
PubMed
4) Lubetsky A, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation : a prospective randomized controlled study. Arch Intern Med. 2003 : 163 ; 2469.
PubMed
5) Yasaka M, et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002 : 108 ; 25.
PubMed
6) Crowther MA, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin : a randomized trial. Ann Intern Med. 2009 ; 150 : 293.
PubMed
7) Sarode R, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding : a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 ; 128 : 1234.
PubMed
8) Goldstein JN, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions : a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 ; 385 : 2077.
PubMed
9) Steiner T, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH) : a randomised trial. Lancet Neurol. 2016 ; 15 : 566.
 
10) Mangram A, et al. Is there a difference in efficacy, safety, and cost effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants? J Crit Care. 2016 ; 33 ; 252.
 
11) Woo CH, et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage : a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2014 ; 81 : 110.
PubMed
12) Barton CA, et al. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa. Am J Surg. 2018 ; 215 : 775.
PubMed
13) 日本脳卒中学会 脳卒中医療向上・社会保険委員会「抗凝固療法中患者への脳梗塞急性期再開通治療に関する推奨」作業部会. 抗凝固療法中患者への脳梗塞急性期再開通治療に関する推奨 2017年11月. http://www.jsts.gr.jp/img/guideline20171222.pdf
 
P.546 掲載の参考文献
1) Sarode R, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding : a randomized, plasma-controlled, phase IIIb study. Circulation 2013 ; 128 : 1234.
PubMed
2) Goldstein JN, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions : a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 ; 385 : 2077.
PubMed
3) Kushimoto S, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures : a prospective, open-label, single-arm phase 3b study. Int J Hematol. 2017 ; 106 : 777.
 
4) van Asch CJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin : a systematic review and meta-analysis. Lancet Neurol. 2010 ; 9 : 167.
PubMed
5) Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet. 2014 ; 383 : 955.
PubMed
6) Steiner T, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH) : a randomised trial. Lancet Neurol. 2016 ; 15 : 566.
 
7) Steiner T, et al. Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 2017 ; 48 : 1432.
PubMed
8) Dentali F, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011 ; 106 : 429.
PubMed
9) Milling TJ Jr, et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal : an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med. 2016 ; 23 : 466.
PubMed
10) Zemrak WR, et al. Low-dose prothrombin complex concentrate for warfarin-associated intracranial hemorrhage with INR less than 2.0. Neurocrit Care. 2017 ; 27 : 334.
 
11) Ostermann H, et al. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007 ; 98 : 790.
PubMed
12) Sin JH, et al. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery : a retrospective evaluation. J Crit Care. 2016 ; 36 : 166-72.
PubMed
13) Dezee KJ, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K) : a meta-analysis. Arch Intern Med. 2006 ; 166 : 391.
PubMed
14) Hemphill JC 3rd, et al. Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015 ; 46 : 2032.
PubMed
15) Zahir H, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015 ; 131 : 82.
PubMed
16) Majeed A, et al. Management of rivaroxaban-or apixaban-associated major bleeding with prothrombin complex concentrates : a cohort study. Blood. 2017 ; 130 : 1706.
 
17) Yoshimura S, et al. Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants : The SAMURAI-NVAF study. J Neurol Sci. 2017 ; 375 : 150.
PubMed
P.561 掲載の参考文献
1) Weitz JI, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 ; 104 : 633.
PubMed
2) Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 2014 ; 383 : 955.
PubMed
3) 家子正裕. 直接経口抗凝固薬 (DOAC) のモニタリング. Vita. 2016 ; 33 : 47.
 
4) Douxfils J, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012 ; 107 : 985.
PubMed
5) Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015 ; 13 : 9.
PubMed
6) Altman R, et al. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban : preliminary results support further tests with all NOACs. Thromb J. 2014 ; 12 : 7.
PubMed
P.565 掲載の参考文献
1) 心房細動治療 (薬物) ガイドライン (2013年改訂版).
 
2) Yasaka M, et al. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001 ; 40 : 1183.
PubMed
3) 小谷英太郎, 他. 心房細動に対するワルファリン療法における日本人の至適INR. J-RHYTHM Registryからの報告. 心電図. 2013 ; 33 : 25.
Medical*Online
4) Gage BF, et al. Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA. 2001 ; 285 : 2864.
 
5) Lip GY, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation. Chest. 2010 ; 137 : 263.
PubMed
6) Okumura K, et al. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation : an analysis of the J-RHYTHM Registry. Circ J. 2014 ; 78 : 1593.
 
7) JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014 ; 78 : 1997.
 
8) Olesen JB, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : nationwide cohort study. BMJ. 2011 ; 342 : d124.
PubMed
9) Shimokawa H, et al. The EXPAND study : Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int J Cardiol. 2018 ; 258 : 126.
PubMed
10) 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 直接経口抗凝固薬 (DOAC) を含めた抗凝固薬に関する追補 2017.
 
P.571 掲載の参考文献
1) van Es N, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism : evidence from phase 3 trials. Blood. 2014 ; 124 : 1968.
PubMed
2) Lee AYY, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer : a randomized clinical trial. JAMA. 2015 ; 314 : 677.
 
3) Raskob GE, et al. Edoxaban for the Treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 ; 378 : 615.
PubMed
4) Young AM, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : results of a randomized trial (SELECT-D). J Clin Oncol. 2018 ; 36 : 2017
 
P.577 掲載の参考文献
1) Hobl EL, et al. A novel vitamin K antagonist. Thromb Haemost. 2017 ; 117 : 2009.
PubMed
2) Hayashi T, et al. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm : a case report. Ann Intern Med. 2014 ; 161 : 158.
 
3) Kadohira Y, et al. Aortic aneurysm-associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med. 2017 ; 56 : 2913.
PubMed
4) John W, et al. Dabigatran versus warfarin in patients with mechanical heart valve. N Engl J Med. 2013 ; 369 : 1206.
 
P.582 掲載の参考文献
1) Pollack CV Jr. et al. Idarucizumab for dabigatran reversal-full cohort analysis. N Engl J Med. 2017 ; 377 : 431.
PubMed
2) Siegal DM, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015 ; 373 : 2413.
PubMed
3) Connolly SJ, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016 ; 375 : 1131.
PubMed
4) Levy JH, et al. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018 ; 15 : 273.
PubMed
5) Galliazzo S, et al. Antidotes for the direct oral anticoagulants : what news? Thromb Res. 2018 ;164 Suppl 1 : S119.
 
P.590 掲載の参考文献
1) 松田保. 止血・血栓の臨床. 東京 : 新興医学出版社 ; 1996.
 
2) Hirsh J, et al. Heparin and low-molecular-weight heparin : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (3 Suppl) : 188S
 
P.595 掲載の参考文献
1) 浦野哲盟. 線溶療法の考え方と治療薬剤. 血栓止血会誌. 2009 ; 20 : 398.
 
2) rt-PA (アルテプラーゼ) 静注療法適性治療指針 第2版. 日本脳卒中学会脳卒中医療向上・社会保険委員会, rt-PA (アルテプラーゼ) 静注療法指針改訂部会. 2012.
 
3) 日本循環器学会, 他. ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版)
 
4) 日本循環器学会, 他. 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版)
 
5) 日本循環器学会, 他. 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版)
 
6) Marti-Fabregas J, et al. Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization. Stroke. 2008 ; 39 : 234.
 
7) Ribo M, et al. Fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004 ; 35 : 2123.
PubMed
8) Campbell BCV, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018 ; 378 : 1573.
PubMed
P.600 掲載の参考文献
1) 浦野哲盟, 他. 血栓形成と凝固・線溶 治療に生かせる基礎医学. 東京 : MEDSi ; 2013.
 
2) Urano T, et al. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost. 2018. doi : 10.1111/jth.14157.
 
3) Wyseure T, et al. Novel or expanding current targets in fibrinolysis. Drug Discov Today. 2014 ; 19 : 1476.
PubMed
4) Iwaki T, et al. Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation. Thromb Haemost. 2017 ; 117 : 860.
 
5) Brzoska T, et al. Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor. Thromb Haemost. 2017 ; 117 : 682.
PubMed
6) Ito Y, et al. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor. Blood Coagul Fibrinolysis. 2018 ; 29 : 314.
PubMed
7) Bridge KI, et al. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease. J Thromb Haemost. 2017 ; 15 : 2218.
 
8) Cale JM, et al. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets. 2007 ; 8 : 971.
PubMed
9) 段孝, 他. Plasminogen activator inhibitor-1 (PAI-1) 分子 : 新たな生理的役割と臨床応用. 臨床血液. 2014 ; 55 : 396.
 
10) Eren M, et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. PNAS. 2014 ; 111 : 7090.
PubMed
11) Khan SS, et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci Adv. 2017 ; 3 : eaao1617.
 
P.606 掲載の参考文献
1) 日本老年医学会. 高齢者の安全な薬物療法ガイドライン 2015. 東京 : メジカルビュー社 ; 2015.
 
2) Yeh RW, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016 ; 315 : 1735.
PubMed
3) 3-5 誤嚥性肺炎の予防. In : 日本脳卒中学会. 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015. p.124.
 
4) Arai H, et al. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease : pilot follow-up study. Am J Geriatr Psychiatry. 2009 ; 17 : 353.
PubMed
5) Rothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer : analysis of individual patient data from randomised trials. Lancet. 2011 ; 377 : 31.
PubMed
6) Wimmer BC, et al. Clinical outcomes associated with medication regimen complexity in older people : a systematic review. J Am Geriatr Soc. 2017 ; 65 : 747.
PubMed
7) Murray MD, et al. Pharmacist intervention to improve medication adherence in heart failure : a randomized trial. Ann Intern Med. 2007 ; 146 : 714.
PubMed
8) Ntaios G, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation : a systematic review and meta-analysis. Stroke. 2017 ; 48 : 2494.
PubMed
9) Andreotti F, et al. Antithrombotic therapy in the elderly : expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015 ; 36 : 3238.
 
10) Ikeda Y, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors : a randomized clinical trial. JAMA. 2014 ; 312 : 2510.
Medical*Online
P.610 掲載の参考文献
1) Rodrigues AD. Integrated cytochrome P450 reaction phenotyping. Biochem Pharmacol. 1999 ; 57 : 465.
PubMed
2) 朝倉英策, 他. 血栓塞栓症, 播種性血管内凝固症候群. In : 病気とくすり 2018. 東京 : 南山堂 ; 2018. p.490.
 
3) Hata T, et al. Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer. Cancer Chemother Pharmacol. 2016 ; 78 : 389.
PubMed
4) 五十嵐弘幸, 他. S-1とワルファリンの薬物相互作用についての検討. 日病薬剤会誌. 2009 ; 45 : 1321.
 
5) 鈴木洋史, 他. これからの薬物相互作用マネジメント 臨床を変えるPISCSの基本と実践. 東京 : じほう ; 2014. p.1.
 

7章 血液製剤・止血剤

P.622 掲載の参考文献
1) 高見昭良, 他. 科学的根拠に基づいた血小板製剤の使用ガイドライン. 日輸血細胞治療会誌. 2017 ; 63 : 569-84.
Medical*Online
P.626 掲載の参考文献
1) 松下正, 他. 科学的根拠に基づいた新鮮凍結血漿 (FFP) の使用ガイドライン. 日輸血細胞治療会誌. 2017 ; 63 : 561.
Medical*Online
P.632 掲載の参考文献
1) 藤井輝久, 他. インヒビターのない血友病患者の止血治療ガイドライン : 2013年改訂版. 血栓止血会誌. 2013 ; 24 : 619.
 
2) Berntorp E, et al. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Semin Thromb Hemost. 2016 ; 42 : 518.
PubMed
3) 藤井輝久, 他. 半減期延長型血友病製剤について. 血栓止血会誌. 2017 ; 28 : 472.
 
4) 鈴木隆史. 血栓止血の臨床 研修医のために. 血液製剤輸血の適応と使用法, 血液凝固因子製剤 (vWF, fibrinogen, factor XIII). 血栓止血誌. 2009 ; 20 : 3.
 
5) Lassila R. Clinical use of factor XIII Concentrates. Semin Thromb Hemost. 2016 ; 42 : 440.
PubMed
P.637 掲載の参考文献
1) Mahlangu J, et al. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 ; 24 : 348.
PubMed
2) Mei B, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010 ; 116 : 270.
PubMed
3) Stennicke HR, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013 ; 121 : 2108.
 
4) Shapiro AD, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012 ; 119 : 666.
 
5) Santagostino E, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 ; 120 : 2405.
PubMed
6) Zollner SB, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013 ; 132 : 280.
PubMed
7) Richards M, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology : guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Brit J Haematol. 2010 ; 149 : 498.
 
8) Collins P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice : guidance from UKHCDO. Haemophilia. 2016 ; 22 : 487.
PubMed
9) Fujii T, et al. Individualized prophylaxis can contribute to decreasing annualized bleeding ratio (ABR) in adult persons with hemophilia A. Haemophilia. 2018 ; 24 (Suppl. 5) : 18.
 
P.643 掲載の参考文献
1) 桑原光弘, 他. 血液製剤の適応と使用法 Factor VIIa製剤. 血栓止血誌. 2009 ; 20 : 571.
 
2) 日本血栓止血学会学術標準化委員会血友病部会. インヒビター保有先天性血友病患者に対する止血治療ガイドライン. 血栓止血誌. 2008 ; 19 : 520.
 
3) 白幡聡, 他. 国内のインヒビター保有血友病患者における遺伝子組換え活性型凝固第VII因子製剤 (注射用ノボセブン(R)) の高用量単回投与に関する臨床研究. 血栓止血誌. 2008 ; 19 : 244.
 
4) 日本血栓止血学会 後天性血友病A診療ガイドライン作成委員会. 後天性血友病A診療ガイドライン. 血栓止血誌. 2011 ; 22 : 295.
 
5) Holme PA, et al. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia. 2018 ; 24 : 24.
PubMed
6) Ingerslev J, et al. Parallel use of by-passing agents in haemophilia with inhibitors : a critical review. Br J Haematol. 2011 ; 155 : 256.
PubMed
7) Konkle BA, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007 ; 5 : 1904.
PubMed
8) 小林隆夫. わが国におけるノボセブンの現況. 日臨麻会誌. 2015 ; 35 : 237.
Medical*Online
P.648 掲載の参考文献
1) 酒井道生, 他. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌. 2013 ; 24 : 619.
 
2) 酒井道生, 他. 後天性血友病A診療ガイドライン : 2017年改訂版. 血栓止血誌. 2017 ; 28 : 715.
 
3) Antunes SV, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014 ; 20 : 65.
 
4) Ogiwara K, et al. Tissue factor passway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor. Int J Hematol. 2014 ; 99 : 577.
 
5) 野上圭嗣. 包括的凝固検査を用いた血友病診療の発展. 血栓止血誌. 2017 ; 28 : 451.
 
6) Ordenburg J, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 ; 377 : 809.
PubMed
P.653 掲載の参考文献
1) インヒビターのない血友病患者に対する止血治療ガイドライン作成委員会. 日本血栓止血学会血友病患者に対する止血治療ガイドライン : 2015年補遺版. 血栓止血誌. 2016 ; 27 : 107.
 
2) 酒井道生, 他. 後天性血友病A診療ガイドライン 2017年改訂版. 血栓止血誌. 2017 ; 28 : 715.
 
3) Shinkoda Y, et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in hemophilia patients with inhibitors. Haemophilia. 2017 ; 23 : 59.
PubMed
4) Shirahata A, et al. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors : haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia. 2013 ; 19 : 853.
 
5) Takedani H, et al. Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent. Haemophilia. 2016 ; 22 : e459.
PubMed
P.657 掲載の参考文献
1) Mannucci P. Miracle of hemophilia drugs : Personal views about a few main players. Haemophilia. 2018. doi : 10.1111/hae.13519. [Epub ahead of print]
 
2) Sampei Z, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibodymimicking the function of factor VIII cofactor activity. PLoS One. 2013 ; 8 : e57479.
 
3) Kitazawa T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia Amodel. Nat Med. 2012 ; 18 : 1570.
 
4) Muto A, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014 ; 124 : 3165.
 
5) Uchida N, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016 ; 127 ; 1633.
 
6) Shima M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016 ; 374 : 2044.
PubMed
7) Shima M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 Study in hemophilia A patients with or without inhibitors. Blood Advance. 2017 ; 1 : 1891.
 
8) Oldenburg J, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 ; 377 : 809.
PubMed
9) Nogami K, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody, emicizumab. JTH. 2018 ; 16 : 1078.
PubMed
10) Nogami K, et al. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. JTH. 2018 May 7 Online First.
 
P.661 掲載の参考文献
1) Martinez-Martinez I, et al. Type II antithrombin deficiency caused by a large in-frame insertion : structural, functional and pathological relevance. J Thromb Haemost. 2012 ; 10 : 1859.
PubMed
2) Iba T, et al. Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. Int J Hematol. 2018 ; 107 : 528.
PubMed
3) Warren BL, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA. 2001 ; 286 : 1869.
PubMed
4) Ruf W, et al. Vascular and dendritic cell coagulation signaling in sepsis progression. J Thromb Haemost. 2009 ; Suppl 1 : 118.
 
5) Kienast J, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal Thromb Haemost. 2006 ; 4 : 90.
 
6) Wiedermann CJ, et al. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006 ; 17 : 521.
PubMed
7) Gando S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013 ; 17 : R297.
PubMed
8) Iba T, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation : a secondary survey. Crit Care. 2014 ; 18 : 497.
PubMed
9) Tagami T, et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation : an observational nationwide study. J Thromb Haemost. 2014 ; 12 : 1470.
PubMed
10) Levi M, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 ; 145 : 24.
PubMed
11) Di Nisio M, et al. Diagnosis and treatment of disseminated intravascular coagulation : guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012 ; 129 : e177.
PubMed
12) Dellinger RP, et al. Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock : 2012. Critical care medicine. 2013 ; 41 : 580.
PubMed
13) 丸山征郎, 他. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 血栓止血会誌. 2009 ; 20 : 77.
 
14) 日本集中治療学会・日本救急医学会. 日本版敗血症診療ガイドライン 2016 (J-SSCG2016) ダイジェスト版. 真興交易医書出版部 ; 2017.
 
15) Iba T, et al. Predicting the severity of SIRS-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma. 2007 ; 63 : 1093.
PubMed
16) Iba T, et al. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2015 ; 135 : 897.
PubMed
17) Iba T, et al. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2016 ; 145 : 46.
PubMed
P.665 掲載の参考文献
1) 池添隆之. トロンボモジュリンの臨床応用. 血栓止血誌. 2014 ; 25 : 61.
 
2) Ikezoe T. Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care. 2015 ; 3 : 1.
PubMed
3) Abeyama K, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005 ; 115 : 1267.
 
4) Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31.
PubMed
5) Matsushita T, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation : a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014 ; 133 : 772.
PubMed
6) Ikezoe T, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res. 2012 ; 36 : 1398.
PubMed
7) Wada H, et al. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res. 2014 ; 134 : 924-5.
 
8) Hayakawa M, et al. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction. Thromb Haemost. 2017 ; 117 : 851.
PubMed
9) Pan B, et al. G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. Sci Rep. 2017 ; 7 : 692.
 
10) Pan B, et al. The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with GPR15. Thromb Haemost. 2017 ; 117 : 570.
PubMed
11) Pan B, et al. The fifth epidermal growth factor-like region of thrombomodulin alleviates murine graft-versus-host disease in a G-protein coupled receptor 15 dependent manner. Biol Blood Marrow Transplant. 2017 ; 23 : 746.
 
P.670 掲載の参考文献
1) 柴田優. 血栓止血の臨床 研修医のために. 止血薬, 抗線溶薬の適応と使用法DDAVP. 血栓止血誌. 2009 ; 20 : 289.
 
2) Kaufmann JE, et al. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003 ; 1 : 682.
PubMed
3) Federici AB. The use of desmopressin in von Willebrand disease : the experience of the first 30 years (1977-2007). Haemophilia. 2008 ; 14 (Suppl 1) : 5.
 
4) Ben-Ami T, et al. The use of DDAVP in children with bleeding disorders. Pediatr Blood Cancer. 2013 ; 60 (Suppl 1) : S41.
 
P.676 掲載の参考文献
1) 金沢大学血液内科・呼吸器内科ブログ : 血液・呼吸器内科のお役立ち情報. 記事カテゴリ : 播種性血管内凝固症候群 (DIC) (図解). http://www.3nai.jp/weblog/archive/category3932.html
 
2) Menell JS, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999 ; 340 : 994.
PubMed
3) CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet. 2010 ; 376 : 23.
 
4) WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN) : an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 ; 389 : 2105.
PubMed
5) CRASH-2 Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients : an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 ; 377 : 1096.
PubMed
6) Gayet-Ageron A, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage : a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet. 2018 ; 391 : 125.
 
7) Myles PS, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017 ; 376 : 136.
PubMed

書評

最近チェックした商品履歴

Loading...